Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Andrés J.M. Ferreri(Vita-Salute San Raffaele University), M. Dreyling(LMU Klinikum), Gerald Illerhaus(Klinikum Stuttgart), Khê Hoang‐Xuan(Pitié-Salpêtrière Hospital), Denis Malaise(Inserm), Maurilio Ponzoni(San Raffaele University of Rome), Kate Cwynarski(University of Leeds), Jacoline E. C. Bromberg(Erasmus MC Cancer Institute), Mats Jerkeman(Lund University), Elisabeth Schorb(University Medical Center Freiburg), C. Buske(University Hospital Ulm), Dorothee P. Auer(University of Nottingham), C. Soussain(Inserm), Christopher P. Fox(Nottingham University Hospitals NHS Trust), Lena Specht(University of Copenhagen), Teresa Calimeri(Vita-Salute San Raffaele University), Emanuele Zucca(Ente Ospedaliero Cantonale), Jeanette K. Doorduijn(Université Paris Cité)
Annals of Oncology
June 1, 2024
10.1016/j.annonc.2023.11.010
Cited by 46

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial
|The Lancet|2005|1k
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
|The Lancet Oncology|2016|738
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2017|736